Xuefeng YU, co-founder, Chief Executive Officer(CEO) and Chairman of CanSino Biologics. He is primarily responsible for overseeing strategic development, overall operations and management as well as being the major decision-making force of our company. In addition, Dr. Yu is also responsible for managing our commercial operations center. He has more than 30 years' experience in biotech research and development. From September 1990 to June 1991, Dr. Yu worked as a lecturer in the Biology Department at Nankai University. From 1996 to 1998, he served as staff scientist at IBEX Technologies, Inc. (a company listed on the Toronto Stock Exchange Venture Exchange, ticker symbol: IBT). Dr. Yu joined Sanofi Pasteur in May 1998 and held the position of director of fermentation development in Canada when he left the company in August 2009.
Shou Bai CHAO, Chief Operating Officer(COO) and Executive Director of CanSino Biologics. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.
Tao ZHU, co-founder, Chief Scientific Officer(CSO) and Executive Director of CanSino Biologics. He is primarily responsible for leading vaccine research and development for CanSinoBIO. In addition, Dr. Zhu also oversees the management of regulatory and clinical affairs. Together with experts from the Academy of Military Medical Sciences, Dr. Zhu led the development and pre-clinical research of the only available recombinant ebola vaccine in China, the production of which was approved by the CFDA. He also led the combinational vaccine project and PBPV project, both of which have been selected as one of the major science and technology projects in the National Twelfth Five-Year Plan for “Significant New Drug Creation” . His achievements also include the establishment of a conjugation technology platform and the development of a variety of vectors including CRM197, plus the process development, pre-clinical research and clinical application of several products, including MCV4, and the invention of seven patents in the PRC.
Dongxu QIU, co-founder, Executive Vice President and Executive Director of CanSino Biologics.He is primarily responsible for advising on the business and strategic development of our company. Dr. Qiu has around 25 years' experience in the biotechnology industry. Dr. Qiu has led several rounds of corporate financing as well as the technology transfers . From January 1993 to April 1997, he was a research scientist at Biomira. Inc. From 1999 to 2000, he served as associate director of product operations at Altarex Inc., responsible for analytical development and product formulation. Dr. Qiu became head of scientific operations at ARIUS Research Inc. from 2000 to 2002, president of Asia at MDS Capital from May 2003 to September 2005, deputy general manager at Shanghai Jima Pharmaceutical Technology Co., Ltd. from 2006 to 2009, and general manager at ChinaBio LLC from March 2007 to April 2011.
Jing WANG, Executive Director and Chief Commercial Officer of CanSino Biologics, is mainly responsible for the company's overall commercial operation. Ms. Wang holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. After joining the Company in June 2012, Ms. Wang has made outstanding achievements in previous positions such as director of personnel，administration department, operation director, financial director and assistant to the chairman. Ms. Wang has led the establishment of our financing, financial operations, human resource and administration systems as well as completing the pre-IPO fundraising of approximately RMB743 million. Ms. Wang successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first “A+H” dual listing vaccine company.
Xi LUO joined the company in September 2021. She serves as chief financial officer, responsible for the company's financial management and capital operation, including the construction and management of the group's financial and internal control system, the development of investment and financing platforms and channels, the decision-making of business operation and investment and financing activities, the compliance governance of listed companies, investor relations management, etc. Ms. Luo has nearly 15 years of experience in brokerage research and investment banking, including IPO of small and medium-sized board, IPO of the Science and Technology Innovation Board, IPO of Second-board Market, refinancing of the Science and Technology Innovation Board, M & A and transfer of control of listed companies. Ms. Luo participated in the IPO of CanSinoBIO, making the company the first “A+H” dual listing vaccine company. Before joining the company, Ms. Luo successfully led IPO, refinancing or M&A of Double Medical Technology Inc., Sinocelltech Group Limited, Sino Biological Inc., Joinn Laboratories (China) Co., Ltd., Novogene Co., Ltd., Changchun BCHT Biotechnology Co., Sansure Biotech Inc. Ms. Luo graduated from Peking Union Medical College and majored in microbiological and biochemical pharmarcy.
Pierre Armand MORGON joined the company as Senior Vice President of International Business Operation in 2020. Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. Currently, Pierre also serves as CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Equity Partners. He is Chairman of the Boards of Theradiag and of Eurocine Vaccines, as well as Non-Executive Director to the Boards of Vaccitech and Univercells. Additionally, he is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. Pierre holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Lifeng XU was appointed as Senior Vice President of Regulatory Affairs and Clinical Operation Center. Mrs. Xu has 27 years of experience in product development, regulatory affairs and project management of vaccines, especially in preventive and therapeutic hepatitis B vaccine, MMR ( measles, mumps and rubella) vaccine, rabies vaccine and varicella vaccine, etc. Prior to CanSinoBIO, she held the position of deputy director of Research and Registration at CNBG where she and her team successfully obtained three new drug licenses and two CTAs. Before entering the bio-pharmaceutical industry, Mrs. Xu earned a medical degree and worked at Chengde Hospital as a physician for 5 years.
Liesheng CHEN, was appointed as Senior Vice President of Manufacturing Center. He graduated from East China University of Science and Technology and has 30 years' experience in biological products production management. He used to serve at the Shanghai Institute of Biological Products research center, Shanghai Rongsheng Biotech CO., LTD., and Walvax Biotechnology Co., Ltd. where he participated in a number of vaccine research and manufacturing projects.
Xiaoman DONG was appointed as Senior Vice President of Quality Center. Mrs. Dong has impressive experience in the area of biological product quality management. She has overseen several vaccine quality management projects, including 15 GMP certifications and re-certifications of vaccine products. In addition, she successfully led quality management for multiple vaccine bulks and freeze-dried preparation workshops, as well as the design, construction, verification and production operation. Mrs. Dong used to hold senior positions at the Lanzhou Institute of Biological Products, Beijing Tiantan Biological Products Co. Ltd., Jiangsu Walvax Biotech Company, etc., She holds a degree from Xi'an Jiao Tong University.
Wei LIU joined the company in August 2021. She serves as Senior Vice President of Organizational Management and Human Resources with a focus on leading the organizational and talents strategy, driving the optimization of corporate culture, and supporting business development and reform. With over 20 years of experience in human resources in multinational companies, Ms. Liu has in-depth insights and experience in organizational development, talent pool construction, salary and welfare, employee training and development. Prior to joining the company, Mrs. Liu served at Alcon (China) Ophthalmic Product .Co. LTD as the head of the Human Resources Department of China and a member of the International Department, where she successfully led several organizational reform and change management projects, as well as organizational efficiency improvement and personnel development. Ms. Liu used to held positions in global Fortune 500 companies, including Hill&Knowlton, Sony Pictures, Honeywell. Ms. Liu holds a master's degree in business administration from Peking University and a general management program certification from Harvard Business School.
Zhongqi SHAO, was appointed vice president for Vaccine Research. Dr. Shao joined CanSino in 2011 as VP of R&D. He is responsible for new antigen discovery and expression, proof of concept studies on new vaccine candidates, as well as analytical science and assay development. Dr. Shao received his Ph.D. in bacterial physiology from Concordia University, and worked as a post-doctoral research fellow at the Soils and Crops Research and Development Centre, Agriculture and Agri-Food Canada.
Guojun ZHAO was appointed as vice president of sales. He used to hold the position of deputy general manager and head of sales in Beijing Tiantan Biological products Co., Ltd (Tiantan Biology). He has been responsible for the sales and management of vaccine for more than 30 years in China National Biotec Group Company Limited, National Vaccine &Serum Institute, etc. Mr. Zhao holds a master's degree in business administration from Tsinghua University.
Yunli XU was appointed as vice president of vaccine research and development in 2020. He is in charge of the R&D of viral and genetic products, as well as the construction and management of GMP pilot plants. With over 30 years of experience in the field of biotechnology, Mr. Xu has led multiple pre-clinical trial projects on gene therapy and is proficient in GMP pilot plant design, sample preparation and manufacturing verification. He used to serve as director in the NIP Pharm and general manager in Vector Gene Technology Company Ltd. Mr. Xu holds a degree of biology from Wuhan University and a degree of genetic engineering and molecular biology from Otsuka Pharmaceutical Co., Ltd.
Willliam joined the Company in October 2020. He was appointed as vice president of the Engineering Service Center, leading engineering service and EHS management. With over 20 years of experience in the project management of the fine chemical and pharmaceutical industry, William has deep insight in design and construction safety management, international quality standard maintaining, as well as project planning and control. He used to serve at SCIDI, Shanghai WSP Consulting LTD., NNE Pharmaplan (Shanghai), Boehringer-Ingelheim (China), Gilead Sciences, Inc. (Hangzhou), Lendlease (Shanghai), etc. William holds a degree of Chemical engineering from the East China University of Science and Technology.
Jian LIU joined the company in April 2021. He serves as Chairman Assistant, Vice President of Corporate Development and Executive Deputy General Manager of CanSino SPH Biologics Inc., subsidiary of CanSino Biologics Inc. Dr. Liu leads the strategic corporate development and the operation of CanSino SPH Biologics lnc. on behalf of CanSino Biologics Inc. Dr. Liu is experienced in enterprise operation, industrial development and government affairs. Across his career, he has participated in driving the operation and reform of large enterprises, strategic development of local industries and technological innovation policy making. Prior to joining the company, he held various senior roles in government and state-owned enterprises, including the General Office of the Tianjin Municipal People’s Government, State-owned Assets Supervision and Administration Commission of Anhui Province, TEDA Administrative Commission, Tianjin Pharmaceuticals and Tianjin TEDA Science& Technology Development Group. Dr. Liu received a Doctorate in pharmaceutical analysis from Institute of Materia Medica of Peking Union Medical College.
Ming Liu joined the company as the vice president of Asset Management & Strategic Investment in June 2021. With 20 years of experience in financial industry, he has expertise in financial management, financial products operation, asset management, strategic investment and financing, risk management, financial technology innovation, etc. Prior to joining the company, Mr. Liu held a number of leadership roles at the Tianjin branch of Shanghai Pudong Development Bank Co., Ltd. including the president of Sci-tech sub-branch and the president of Puxin sub-branch. Mr. Liu holds a bachelor’s degree in accounting and an MBA from Nankai University.
Hongyi Wang joined the company as the vice president of International Business in June 2021, responsible for driving the company’s marketing, management and operation of international business as well as implementing international business development strategy. With over 20 years of experience in corporate management and international business development, he has successfully led the international market development and trade of medical products, and has experience in the establishment of branches overseas. He also participated in various rounds of investment in China’s medical & pharmaceutical fields made by foreign corporations. Mr. Wang used to respectively hold senior roles at Tasly Holding Group, HNA Group Co., Ltd, etc., and spent years working abroad. Mr. Wang obtained his bachelor’s degree in French Diplomacy from China Foreign Affairs University and his EMBA degree from Nankai University.
Jin CUI was appointed as the secretary of the Board in September, 2021. He is responsible for management of affairs in relation to capital market, investor relations management, assisting the board of directors in formulating development strategy in capital market, formulation and implementation of capital operation projects and focuses on compliance and corporate governance. Mr. Cui holds a master's degree in international financial analysis and a bachelor's degree in actuarial and risk management. Since 2016, he has successively served as executive manager of strategic development, assistant to the chairman, head of securities affairs department, joint company secretary and securities affairs representative.